{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:08:00Z","timestamp":1788826080427,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.htct.2025.106240","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:52:44Z","timestamp":1768031564000},"page":"106240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-9197","authenticated-orcid":false,"given":"Lena","family":"Avinery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Khamaisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9289-8898","authenticated-orcid":false,"given":"Jacob","family":"Gopas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-2039","authenticated-orcid":false,"given":"Jamal","family":"Mahajna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.htct.2025.106240_bib0001","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.htct.2025.106240_bib0002","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.htct.2025.106240_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.htct.2025.106240_bib0004","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3109\/10428194.2011.589551","article-title":"Cancer microenvironment, extracellular matrix, and adhesion molecules: the bitter taste of sugars in chronic lymphocytic leukemia","volume":"52","author":"Katz","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.htct.2025.106240_bib0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.leukres.2011.08.001","article-title":"Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy","volume":"36","author":"Tesfai","year":"2012","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.htct.2025.106240_bib0006","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1349-7006.2012.02408.x","article-title":"Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors","volume":"103","author":"Minakata","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.htct.2025.106240_bib0007","unstructured":"Jensen P.\u00c9., Mortensen B.T., Hodgkiss R.J., Iversen P.O., Christensen I.J., Helledie N., et al. Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats."},{"issue":"1","key":"10.1016\/j.htct.2025.106240_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2013","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.htct.2025.106240_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086459","article-title":"Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor","volume":"9","author":"Murakami","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.htct.2025.106240_bib0010","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","article-title":"Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations","volume":"123","author":"Traer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.htct.2025.106240_bib0011","article-title":"Crizotinib overcomes microenvironment-mediated drug resistance in ph-positive leukemia","volume":"10","author":"Regev","year":"2018","journal-title":"Cancer Sci Ther"},{"issue":"21","key":"10.1016\/j.htct.2025.106240_bib0012","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","article-title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition","volume":"123","author":"Ng","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.htct.2025.106240_bib0013","doi-asserted-by":"crossref","DOI":"10.21037\/tp-21-86","article-title":"Hypoxia induces inflammatory microenvironment by priming specific macrophage polarization and modifies LSC behaviour via VEGF-HIF1\u03b1 signalling","volume":"10","author":"Jiang","year":"2021","journal-title":"Transl Pediatr"},{"issue":"19","key":"10.1016\/j.htct.2025.106240_bib0014","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.7150\/jca.19633","article-title":"Ectopic expression of snail and twist in ph+ leukemia cells upregulates CD44 expression and alters their differentiation potential","volume":"8","author":"Kidan","year":"2017","journal-title":"J Cancer"},{"issue":"6","key":"10.1016\/j.htct.2025.106240_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/MCB.01514-06","article-title":"The hypoxia-inducible factor 2 N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis In vivo \u2020","volume":"27","author":"Yan","year":"2007","journal-title":"Mol Cell Biol."},{"issue":"4","key":"10.1016\/j.htct.2025.106240_bib0016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1261\/rna.2192803","article-title":"Lentivirus-delivered stable gene silencing by RNAi in primary cells","volume":"9","author":"Stewart","year":"2003","journal-title":"RNA"},{"issue":"8","key":"10.1016\/j.htct.2025.106240_bib0017","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.acthis.2012.02.004","article-title":"The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans","volume":"114","author":"Gochman","year":"2012","journal-title":"Acta Histochem"},{"issue":"9","key":"10.1016\/j.htct.2025.106240_bib0018","doi-asserted-by":"crossref","first-page":"7730","DOI":"10.3390\/ijms24097730","article-title":"Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to ovarian cancer cells","volume":"24","author":"Koren Carmi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.htct.2025.106240_bib0019","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1080\/01635581.2011.607542","article-title":"Inhibition of the androgen receptor activity by Coprinus comatus substances","volume":"63","author":"Dotan","year":"2011","journal-title":"Nutr Cancer"},{"issue":"2","key":"10.1016\/j.htct.2025.106240_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/2278-330X.110506","article-title":"Crizotinib: a comprehensive review","volume":"2","author":"Sahu","year":"2013","journal-title":"South Asian J Cancer"},{"issue":"1","key":"10.1016\/j.htct.2025.106240_bib0021","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5114\/aoms.2020.101042","article-title":"Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells","volume":"17","author":"Regev","year":"2021","journal-title":"Arch Med Sci"},{"issue":"54","key":"10.1016\/j.htct.2025.106240_bib0022","first-page":"e2899","article-title":"Induction and testing of hypoxia in cell culture","author":"Wu","year":"2011","journal-title":"J Vis Exp"},{"issue":"9","key":"10.1016\/j.htct.2025.106240_bib0023","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1002\/ijc.24601","article-title":"Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3","volume":"125","author":"Selvendiran","year":"2009","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.htct.2025.106240_bib0024","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon.11.81","article-title":"Ruxolitinib: a new JAK1\/2 inhibitor that offers promising options for treatment of myelofibrosis","volume":"7","author":"Ostojic","year":"2011","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.htct.2025.106240_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088955","article-title":"Proline-hydroxylated hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) upregulation in Human tumours","volume":"9","author":"Snell","year":"2014","journal-title":"PLoS One"},{"issue":"6892","key":"10.1016\/j.htct.2025.106240_bib0026","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL","volume":"417","author":"Hon","year":"2002","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.htct.2025.106240_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044078","article-title":"Hypoxia regulates CD44 and its variant isoforms through HIF-1\u03b1 in triple negative breast cancer","volume":"7","author":"Krishnamachary","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.htct.2025.106240_bib0028","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1535-6108(03)00077-1","article-title":"2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF","volume":"3","author":"Mabjeesh","year":"2003","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.htct.2025.106240_bib0029","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/cbt.20838","article-title":"Regulation of HIF-1\u03b1 signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment","volume":"13","author":"Frolova","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"10.1016\/j.htct.2025.106240_bib0030","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00277-020-04357-z","article-title":"Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K","volume":"100","author":"Mian","year":"2021","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.htct.2025.106240_bib0031","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/17460441.2019.1613370","article-title":"The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy","volume":"14","author":"Albadari","year":"2019","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"10.1016\/j.htct.2025.106240_bib0032","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3892\/ijo.2014.2574","article-title":"Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition","volume":"45","author":"Kogita","year":"2014","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.htct.2025.106240_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065304","article-title":"Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha","volume":"8","author":"Adamski","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.htct.2025.106240_bib0034","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jbo.2016.01.002","article-title":"Hypoxia promotes drug resistance in osteosarcoma cells via activating AMP-activated protein kinase (AMPK) signaling","volume":"5","author":"Zhao","year":"2016","journal-title":"J Bone Oncol"},{"issue":"4","key":"10.1016\/j.htct.2025.106240_bib0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1152\/physiol.00036.2016","article-title":"Modeling physiological events in 2D vs. 3D cell culture","volume":"32","author":"Duval","year":"2017","journal-title":"Physiology"},{"issue":"6194","key":"10.1016\/j.htct.2025.106240_bib0036","article-title":"Organogenesisin a dish: modeling development and disease using organoid technologies","volume":"345","author":"Lancaster","year":"2014","journal-title":"Science (1979)"},{"issue":"15","key":"10.1016\/j.htct.2025.106240_bib0037","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2174\/1381612824666180404152304","article-title":"Comparative assay of 2D and 3D cell culture models: proliferation, gene expression and anticancer drug response","volume":"24","author":"Souza","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.htct.2025.106240_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2776-1","article-title":"Hypoxia promotes chemoresistance in acute lymphoblastic leukemia cell lines by modulating death signaling pathways","volume":"16","author":"Petit","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.htct.2025.106240_bib0039","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.oraloncology.2018.03.004","article-title":"Hypoxia induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC","volume":"80","author":"Joseph","year":"2018","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.htct.2025.106240_bib0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13277-015-3816-1","article-title":"2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma","volume":"37","author":"Lin","year":"2016","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/j.htct.2025.106240_bib0041","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00280-008-0679-9","article-title":"2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft","volume":"62","author":"Azab","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.htct.2025.106240_bib0042","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood-2002-02-0376","article-title":"2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells","volume":"100","author":"Chauhan","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2025.106240_bib0043","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1592\/phco.23.2.165.32088","article-title":"2-Methoxyestradiol, a promising anticancer agent","volume":"23","author":"Lakhani","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.htct.2025.106240_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27030804","article-title":"2-Hydroxyestradiol overcomes mesenchymal stem cells-mediated platinum chemoresistance in ovarian cancer cells in an ERK-independent fashion","volume":"27","author":"Khamaisi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.htct.2025.106240_bib0045","article-title":"Combined effects of 2-methoxyestradiol (Hypoxia-Inducible Factor 1\u03b1 Inhibitor) and dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on chronic myelocytic leukemia cells","volume":"2022","author":"Zhang","year":"2022","journal-title":"J Immunol Res"},{"issue":"3","key":"10.1016\/j.htct.2025.106240_bib0046","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ijc.23117","article-title":"2-Methoxyestradiol modulates \u03b2-catenin in prostate cancer cells: a possible mediator of 2-methoxyestradiol-induced inhibition of cell growth","volume":"122","author":"Van Veldhuizen","year":"2008","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.htct.2025.106240_bib0047","first-page":"468","article-title":"2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway","volume":"63","author":"LaVallee","year":"2003","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.htct.2025.106240_bib0048","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3109\/10428194.2012.733874","article-title":"Hypoxia inducible factor-1\u03b1 induces chemoresistance phenotype in non-hodgkin lymphoma cell line via up-regulation of bcl-xL","volume":"54","author":"Hernandez-Luna","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.htct.2025.106240_bib0049","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.2174\/092986712802002554","article-title":"AG490 promotes HIF-1\u03b1 accumulation by inhibiting its hydroxylation","volume":"19","author":"Fernandez-Sanchez","year":"2012","journal-title":"Curr Med Chem"},{"issue":"18","key":"10.1016\/j.htct.2025.106240_bib0050","doi-asserted-by":"crossref","first-page":"13672","DOI":"10.1074\/jbc.M700534200","article-title":"Hypoxia-inducible factor-1 alpha inhibits self-renewal of mouse embryonic stem cells in Vitro via negative regulation of the leukemia inhibitory factor-STAT3 pathway","volume":"282","author":"Jeong","year":"2007","journal-title":"J Biol Chem"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925025040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925025040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:24:50Z","timestamp":1788823490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137925025040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2531137925025040"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2025.106240","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2025.106240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"106240"}}